PALB2 and cancer: The authors also acknowledge that there has not been much research on PALB2 pathogenic mutations in PCa patients, but research conducted in Poland in 2021 by Wokolorczyk and others found that aggressive cancers with high Gleason scores of 8–10 were more frequently diagnosed with the two founder mutations of PALB2 c.509_510delGA and c.172_ 175delTTGT, which together account for 80% of all PALB2 mutations.